vs
Side-by-side financial comparison of Maase Inc. (MAAS) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $9.9M, roughly 1.9× Maase Inc.). Maase Inc. produced more free cash flow last quarter ($-18.3M vs $-37.8M).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
MAAS vs NAMS — Head-to-Head
Income Statement — Q2 FY2023 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.9M | $19.1M |
| Net Profit | — | $-17.4M |
| Gross Margin | 78.7% | — |
| Operating Margin | -55.9% | -186.1% |
| Net Margin | — | -90.7% |
| Revenue YoY | — | 740.1% |
| Net Profit YoY | — | 55.5% |
| EPS (diluted) | — | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | — | $19.1M | ||
| Q4 24 | — | $12.8M | ||
| Q3 24 | — | $29.1M | ||
| Q2 23 | — | $8.6M | ||
| Q4 22 | $9.9M | — |
| Q2 25 | — | $-17.4M | ||
| Q4 24 | — | $-92.2M | ||
| Q3 24 | — | $-16.6M | ||
| Q2 23 | — | $-42.0M | ||
| Q4 22 | — | — |
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | 78.7% | — |
| Q2 25 | — | -186.1% | ||
| Q4 24 | — | -338.5% | ||
| Q3 24 | — | -85.9% | ||
| Q2 23 | — | -461.8% | ||
| Q4 22 | -55.9% | — |
| Q2 25 | — | -90.7% | ||
| Q4 24 | — | -721.7% | ||
| Q3 24 | — | -57.2% | ||
| Q2 23 | — | -486.9% | ||
| Q4 22 | — | — |
| Q2 25 | — | $-0.15 | ||
| Q4 24 | — | $-0.91 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 23 | — | $-0.51 | ||
| Q4 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.9M | $739.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $31.6M | $778.5M |
| Total Assets | $47.0M | $815.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $739.2M | ||
| Q4 24 | — | $834.2M | ||
| Q3 24 | — | $422.7M | ||
| Q2 23 | — | — | ||
| Q4 22 | $10.9M | — |
| Q2 25 | — | $778.5M | ||
| Q4 24 | — | $757.5M | ||
| Q3 24 | — | $378.9M | ||
| Q2 23 | — | $398.4M | ||
| Q4 22 | $31.6M | — |
| Q2 25 | — | $815.1M | ||
| Q4 24 | — | $864.6M | ||
| Q3 24 | — | $439.2M | ||
| Q2 23 | — | — | ||
| Q4 22 | $47.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.2M | $-37.7M |
| Free Cash FlowOCF − Capex | $-18.3M | $-37.8M |
| FCF MarginFCF / Revenue | -184.4% | -197.2% |
| Capex IntensityCapex / Revenue | 1.0% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-119.7M |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $-37.7M | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.5M | ||
| Q2 23 | — | $-31.9M | ||
| Q4 22 | $-18.2M | — |
| Q2 25 | — | $-37.8M | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.6M | ||
| Q2 23 | — | $-31.9M | ||
| Q4 22 | $-18.3M | — |
| Q2 25 | — | -197.2% | ||
| Q4 24 | — | -293.5% | ||
| Q3 24 | — | -43.2% | ||
| Q2 23 | — | -369.3% | ||
| Q4 22 | -184.4% | — |
| Q2 25 | — | 0.5% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 23 | — | 0.1% | ||
| Q4 22 | 1.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MAAS
| Wealth management | $7.8M | 78% |
| Insurance consulting | $1.0M | 10% |
| Other | $975.0K | 10% |
| Asset management | $168.0K | 2% |
NAMS
Segment breakdown not available.
